Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness unloads nutritionals

This article was originally published in The Tan Sheet

Executive Summary

The maker of consumer diagnostic devices sells its legacy nutritionals business for $63.4 million in cash to International Vitamin Corporation, Inverness Medical Innovations announces Jan. 19. Inverness Medical Nutritionals generated net revenues of $63.6 million and an operating loss of $2.4 million in the first nine months of 2009, the Waltham, Mass., company said. The unit's supplement products include Stresstabs vitamins, Posture-D calcium supplements and Ferro-Sequels iron supplements. Inverness moved into smoking-cessation and other therapeutic services with its $100 million acquisition of Free & Clear Inc. (1"The Tan Sheet" Nov. 2, 2009)

You may also be interested in...



Inverness alters name to Alere

Medical diagnostic firm Inverness Medical Innovations seeks shareholder approval to rechristen itself Alere - the name of its health management services business. The change announced May 18 reflects the firm's continuing evolution toward integrated health management and therapeutic services and away from legacy operations, such as the nutritionals business it divested in January (1"The Tan Sheet" Jan. 25, 2010, In Brief). Inverness, based in Waltham, Mass., also announced first-quarter net revenue of $515.3 million, a 21.2 percent gain. Revenue from the consumer diagnostics unit fell 24 percent to $24.7 million in the January-March period, Inverness said April 28. However, product revenues from the company's joint venture with Procter & Gamble rose 15 percent to $55.9 million. Inverness' quarterly net income jumped 118.5 percent to $14.2 million

Sales & Earnings In Brief

Launches underlie Reckitt consumer growth: Recent line extensions, including Nurofen Express pain reliever and Strepsils Cool throat lozenges, enable Reckitt Benckiser's Health & Personal Care business to grow 16 percent to $869.5 million (533 million U.K. pounds under Oct. 27 conversion rates) during the fiscal 2009 third quarter. "Those products are doing extremely well and clearly underpin the growth rate that we are seeing" in the segment, CEO Bart Becht said Oct. 27. In a same-day release, the U.K. firm cited Dettol hygiene products, Gaviscon antacid and Mucinex cough/cold remedy as major growth drivers. Becht told analysts to expect additional launches in February 2010. Reckitt reported overall net revenue of $3.1 billion in the July-September period, a 7 percent gain. Quarterly net income was $582.4 million, up 12 percent

More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

Topics

UsernamePublicRestriction

Register

PS103728

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel